Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  metformin hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 31 for your search:
Start Over
Paclitaxel and Carboplatin with or without Metformin Hydrochloride in Treating Patients with Stage III, IV, or Recurrent Endometrial Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0286B, NCI-2013-02284, NCT02065687
Metformin Hydrochloride with or without Lifestyle Intervention in Preventing Endometrial Cancer in Obese Post-Menopausal Patients with High Insulin Levels
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Age: 50 to 60
Trial IDs: 2011-0739, NCI-2013-00834, NCT01697566
Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 to 55
Trial IDs: A211102, NCI-2013-00995, CALGB-A211102, NCT01905046
Exercise and Metformin Hydrochloride in Lowering Insulin Levels in Colorectal or Breast Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training, Treatment
Age: 18 and over
Trial IDs: 11-009, NCI-2011-02702, NCT01340300
Dasatinib in Preventing Second Primary Breast Cancer in Women with Estrogen Receptor Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 2010-0794, NCI-2012-00037, KG09 1020, Susan Komen Foundation Grant Number(s): KG09 1020, NCT01471106
Metformin Hydrochloride and Simvastatin in Treating Patients With Recurrent Prostate Cancer After Surgery and/or Radiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: H-28936, NCI-2013-01344, H-28989, NCT01561482
Metformin Hydrochloride in Preventing Relapse in Patients with Stage IIC/III/IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Treatment
Age: 19 to 79
Trial IDs: HUM00047900, NCI-2012-00384, HUM 47900, UMCC 2011.037, NCT01579812
Metformin Hydrochloride, Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients with Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE 1212, NCI-2012-01322, NCT01666730
Everolimus, Letrozole, and Metformin Hydrochloride in Treating Patients with Advanced or Recurrent Endometrial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0543, NCI-2013-00960, RAD001CUS195T, NCT01797523
Metformin Hydrochloride in Reducing Obesity-Associated Breast Cancer Risk
Phase: Phase II
Type: Prevention
Age: 30 to 45
Trial IDs: 1300000596, NCI-2015-01211, 1300000596A024, NCT02028221
Metformin Hydrochloride and Combination Chemotherapy in Treating Patients with Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 77
Trial IDs: UC IRB13-1235, NCI-2014-00860, NCT02122185
Chemotherapy and Radiation Therapy with or without Metformin Hydrochloride in Treating Patients with Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-LU001, NCI-2014-01071, PNRG-LU001_A01PAMDREVW01, NCT02186847
Metformin Hydrochloride in Treating Patients with Non-small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0255, NCI-2015-00287, NCT02285855
Metformin Hydrochloride in Reducing Treatment-Related Neuropathy in Patients with Stage I-IV Breast Cancer Undergoing Treatment with Paclitaxel
Phase: Phase II
Type: Supportive care
Age: Over 18
Trial IDs: 2014-0438, NCI-2015-00510, NCT02360059
Weight Loss or Metformin Hydrochloride in Reducing IGF-1 Hormone in Cancer Survivors
Phase: Phase II
Type: Behavioral study
Age: 18 and over
Trial IDs: J14148, NCI-2015-01160, NCT02431676
Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)
Phase: Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: MCC-16601, NCI-2011-02772, 14.03.0082, NCT01324180
Metformin Hydrochloride, Vincristine Sulfate, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: MCC 16962, NCI-2013-01179, NCT01528046
Temsirolimus and Metformin Hydrochloride in Treating Patients with Advanced or Metastatic Cancer
Phase: Phase I
Type: Treatment
Age: 14 and over
Trial IDs: 2011-0923, NCI-2012-00216, NCT01529593
Metformin Hydrochloride and Erlotinib Hydrochloride in Treating Patients With Triple Negative Metastatic Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 to 79
Trial IDs: AAAF3743, NCI-2013-01192, CF-AAAN0203, IRB-AAAF3743, NCT01650506
Metformin Hydrochloride and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 11H03, NCI-2011-01084, MOD0002, STU00048047, NCT01849276
Metformin Hydrochloride in Reducing Cancer Risk in Patients with Li-Fraumeni Syndrome
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 14-C-0005, NCI-2014-02320, 140005, P121103, NCT01981525
Metformin Hydrochloride With or Without Sirolimus After Induction Chemotherapy Therapy in Treating Patients With Metastatic Pancreatic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: J13146, NCI-2014-00912, NA_00090282, NCT02048384
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN-062, NCI-2013-02223, IRB#13-033, NCT02050009
Metformin Hydrochloride in Treating Patients with Endometrial Hyperplasia
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: LCCC 1205, NCI-2013-02235, 12-0886, NCT01685762
Start Over